**Primary Education:** * Graduated from Sun Yat-sen University of Medical Sciences in 1984, completing master's and doctoral training. * Studied at the University of Alabama at Birmingham (UAB), USA, for one year from 2002 to 2003. **Social Appointments:** * Vice Chairman, Chinese Medical Association, Endocrinology Branch * Chairman, Guangdong Medical Association, Endocrinology Branch * Vice Chairman, Chinese Microcirculation Society, Diabetes and Microcirculation Professional Committee * Leader, Chinese Insulin Secretion Research Group * National Leading Medical Talent in Guangdong Province, Guangdong Youyue Talent * Chief Expert, National Key Special Project for Major Chronic Diseases * Third-term Chairman, Guangdong Medical Association, Diabetes Branch * Chairman, Guangdong Health Management Association, Metabolism and Endocrinology Professional Committee * Member, Guangdong Provincial Cadre Health Expert Group * Director, Key Laboratory of Guangdong Provincial Health Department * Director, National Endocrine Pharmacology Base, The First Affiliated Hospital, Sun Yat-sen University **Landmark Achievements:** * Intense simplified strategy for newly diagnosed type 2 diabetes in patients with severe hyperglycaemia: multicentre, open label, randomised trial; BMJ. 2024 Oct 15:387:e080122. (Q1, IF 93.6) **Introduction:** Professor Yanbing Li has long been dedicated to research on reversing type 2 diabetes through early short-term intensive insulin therapy. In 2000, she pioneered the application of short-term intensive insulin therapy as initial treatment for type 2 diabetes in China. Related findings were published in *Diabetes Care* (2004, 2012; IF 14.8), significantly improving patient outcomes and inducing diabetes remission. Subsequently, through national multicenter studies, she further established the important role of Short-term Intensive Insulin Therapy (SIIT) in diabetes treatment paradigms, with results published in *The Lancet* (2008; IF 98.4). She was the first in China to propose the "Precision Step-down Treatment Model" for type 2 diabetes. Through in-depth analysis, her team identified a series of clinical markers predictive of long-term glycemic remission and summarized insulin dosage and glycemic characteristics during intensive therapy. Related findings were published in journals such as *Endocr J* (2013), *Diabetes Technol Ther* (2013), *Diabetes Res Clin Prac* (2015, 2017), *J Diabetes Res* (2016), and *J Diabetes* (2023). Her team continuously explores optimization and mechanistic studies of insulin intensification regimens, refining and standardizing the intensive treatment protocol. Since 2017, based on prior research, her team developed the "Intensification-Simplification" treatment strategy, validated through a national multicenter randomized controlled trial. The study found this strategy significantly improved glycemic control, markedly outperforming current standard treatment strategies, with results published in *BMJ* (2024; IF 93.6). The team established the largest cohort globally (over 2000 cases) of newly diagnosed type 2 diabetes patients undergoing short-term intensive insulin therapy, with the longest follow-up and most comprehensive samples. These research findings have been adopted by multiple editions of the Chinese Diabetes Prevention and Treatment Guidelines (2013-2024), serving as a crucial basis for the short-term intensive insulin therapy pathway in newly diagnosed patients and the selection of post-intensive therapy glucose-lowering regimens, profoundly impacting the treatment methods and concepts for type 2 diabetes. Furthermore, she led the drafting of the *Expert Consensus on Short-term Intensive Insulin Therapy for Reversing Type 2 Diabetes* and the *Expert Consensus on Short-term Intensive Insulin Therapy for Type 2 Diabetes (2021 Edition)*, generating significant impact within the field. She also led the establishment of the Short-term Intensive Insulin Therapy Specialist Alliance and the Guangdong Diabetes Remission Management Alliance, effectively promoting the standardized development of intensive therapy and diabetes reversal efforts. **Monographs:** * *Clinical Diagnosis and Treatment Protocols for Endocrinology and Rheumatology*, Scientific and Technical Documentation Press * *300 Most Concerned Questions for Diabetic Patients*, Hubei Science and Technology Press * *Introduction to Prescription Science*, Hubei Science and Technology Press **Awards:** * Second Prize, National Science and Technology Progress Award (2011, 2nd Completer) * First Prize, Guangdong Provincial Science and Technology Progress Award (2008, 2nd Completer) * First Prize, Ministry of Education Science and Technology Progress Award (2007, 3rd Completer)